Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
Authors
Keywords
Clinical trials, Nephropathy, Obesity, Pathophysiology, SGLT2 inhibitors
Journal
Diabetes Therapy
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-07-11
DOI
10.1007/s13300-018-0470-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
- (2018) Motoshi Ouchi et al. DIABETES OBESITY & METABOLISM
- Pre-sarcopenia is associated with renal hyperfiltration independent of obesity or insulin resistance
- (2017) Eugene Han et al. MEDICINE
- The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study
- (2017) So Ra Kim et al. Diabetes Therapy
- The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study
- (2017) So Ra Kim et al. Diabetes Therapy
- Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
- (2017) Kyung-Wan Min et al. Diabetes & Metabolism Journal
- Higher glomerular filtration rate is related to insulin resistance but not to obesity in a predominantly obese non-diabetic cohort
- (2017) Negar Naderpoor et al. Scientific Reports
- A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes
- (2016) Eugene Han et al. MEDICINE
- The Association of Serum Cystatin C with Glycosylated Hemoglobin in Korean Adults
- (2016) Eun Hee Sim et al. Diabetes & Metabolism Journal
- Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
- (2015) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes
- (2015) Yuta Nakamura et al. EXPERT OPINION ON PHARMACOTHERAPY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
- (2014) Yukihiro Chino et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Prevalence, Awareness, and Management of Obesity in Korea: Data from the Korea National Health and Nutrition Examination Survey (1998-2011)
- (2014) Chul Sik Kim et al. Diabetes & Metabolism Journal
- A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
- (2014) Chang Hee Jung et al. Diabetes & Metabolism Journal
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
- (2012) J. Rosenstock et al. DIABETES CARE
- Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
- (2012) R. R. Henry et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glomerular hyperfiltration: definitions, mechanisms and clinical implications
- (2012) Imed Helal et al. Nature Reviews Nephrology
- Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
- (2011) Muhammad A. Abdul-Ghani et al. ENDOCRINE REVIEWS
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
- (2010) L. Zhang et al. DIABETES OBESITY & METABOLISM
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Elevated Serum Uric Acid Concentrations Independently Predict Cardiovascular Mortality in Type 2 Diabetic Patients
- (2009) G. Zoppini et al. DIABETES CARE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started